Fennec Pharmaceuticals Inc.
FRX.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -8.38M | -9.74M | -6.94M | -12.04M | -14.44M |
| Total Depreciation and Amortization | 0.00 | 0.00 | -697.00K | -698.00K | -697.00K |
| Total Amortization of Deferred Charges | 52.00K | 65.00K | 133.00K | 142.00K | 152.00K |
| Total Other Non-Cash Items | 12.10M | 12.04M | 5.20M | 10.90M | 9.59M |
| Change in Net Operating Assets | -9.55M | -14.83M | -5.68M | -9.99M | -10.99M |
| Cash from Operations | -5.78M | -12.47M | -7.99M | -11.68M | -16.39M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -19.48M | -19.48M | -13.00M | -13.00M | -13.00M |
| Issuance of Common Stock | 45.38M | 44.42M | 2.97M | 1.17M | 1.52M |
| Repurchase of Common Stock | -671.00K | -372.00K | -355.00K | -833.00K | -639.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.95M | -1.95M | 0.00 | 0.00 | 0.00 |
| Cash from Financing | 23.28M | 22.63M | -10.39M | -12.67M | -12.12M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 17.50M | 10.15M | -18.37M | -24.35M | -28.51M |